PE20030820A1 - Analogos extendidos de peptido 1 de tipo glucagon - Google Patents
Analogos extendidos de peptido 1 de tipo glucagonInfo
- Publication number
- PE20030820A1 PE20030820A1 PE2003000021A PE2003000021A PE20030820A1 PE 20030820 A1 PE20030820 A1 PE 20030820A1 PE 2003000021 A PE2003000021 A PE 2003000021A PE 2003000021 A PE2003000021 A PE 2003000021A PE 20030820 A1 PE20030820 A1 PE 20030820A1
- Authority
- PE
- Peru
- Prior art keywords
- ser
- lys
- arg
- ala
- pro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE REFIERE A UN PEPTIDO 1 DE TIPO GLUCAGON GLP-1 EXTENDIDO QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS 1; DONDE Xaa7 ES HISTIDINA, DESAMINOHISTIDINA, 2-AMNOHISTIDINA, ß-HIDROXIHISTIDINA, HOMOHISTIDINA, O-FLUOROMETILHISTIDINA, O-METILHISTIDINA; Xaa8 ES ALA, GLY, VAL, LEU, ILE, SER, THR; Xaa12 ES PHE, TRP, TYR, Xaa16 ES VAL, TRP, LEU, PHE, TYR; Xaa18 ES SER, TRP, TYR, PHE, LYS, ILE, LEU, VAL; Xaa19 ES TYR, TRP, PHE; Xaa20 ES LEU, PHE, TYR, TRP; Xaa22 ES GLY, GLU, ASP, LYS; Xaa25 ES ALA, VAL, ILE, LEU; Xaa27 ES GLU, ILE, ALA; Xaa30 ES ALA, GLU, Xaa33 ES VAL, ILE; Xaa34 ES LYS, ASP, ARG, GLU; Xaa36 ES GLY, PRO, ARG; Xaa37 ES GLY, PRO, SER; Xaa38 ES SER, PRO, HIS; Xaa39 ES SER, ARG, THR, TRP, LYS; Xaa 40 ES SER, GLY; Xaa41 ES ALA, ASP, ARG, GLU, LYS, GLY, Xaa42 ES PRO, ALA, NH2; Xaa43 ES PRO, ALA, NH2; Xaa44 ES PRO, ALA, ARG, LYS, HIS, NH2, XAA45 ES SER, HIS, PRO, LYS, ARG, NH2, Xaa46 ES HIS, SER, ARG, NH2; Xaa47 ES HIS, SER, ARG, LYS, NH2; SI Xaa42-Xaa47 ESTAN AUSENTES CADA AMINOACIDO CADENA ABAJO ESTA AUSENTE, ENTRE OTRAS CONDICIONES; CARACTERIZADO PORQUE LOS PRIMEROS 31 AMINOACIDOS DEL PEPTIDO NO DIFIEREN DE GLP-1(7-37) EN MAS DE 6 AMINOACIDOS. EL PEPTIDO GLP-1 AL QUE SE HAN ANADIDO AMINOACIDOS EN C-TERMINAL PRESENTA SEMIVIDA SERICA MAS LARGA Y ES ADECUADO PARA ADMINISTRACION ORAL Y PULMONAR DEBIDO A QUE ES RESISTENTE A ENZIMAS PROTEOLITICAS Y PUEDE SER UTIL PARA LA ESTIMULACION DEL RECEPTOR DE GLP-1 EN UN SUJETO NECESITADO DE NORMALIZACION DE GLUCOSA EN SANGRE COMO DIABETES N
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34647402P | 2002-01-08 | 2002-01-08 | |
| US40509702P | 2002-08-21 | 2002-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030820A1 true PE20030820A1 (es) | 2003-10-04 |
Family
ID=26994870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000021A PE20030820A1 (es) | 2002-01-08 | 2003-01-06 | Analogos extendidos de peptido 1 de tipo glucagon |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7482321B2 (es) |
| EP (1) | EP1585959A4 (es) |
| JP (1) | JP4282485B2 (es) |
| AR (1) | AR038102A1 (es) |
| AU (1) | AU2003200839B2 (es) |
| BR (1) | BR0306706A (es) |
| CA (1) | CA2468700A1 (es) |
| MX (1) | MXPA04006679A (es) |
| PE (1) | PE20030820A1 (es) |
| TW (1) | TW200306202A (es) |
| WO (1) | WO2003058203A2 (es) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0407936A (pt) | 2003-03-19 | 2006-02-21 | Lilly Co Eli | composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado |
| JP4865565B2 (ja) | 2003-12-09 | 2012-02-01 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アゴニストを用いた食物選択の制御 |
| CA2552526A1 (en) | 2004-01-08 | 2005-07-21 | Theratechnologies Inc. | Glucagon-like peptide-1 analogs with long duration of action |
| JP2008501765A (ja) | 2004-06-11 | 2008-01-24 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和 |
| CA2577010A1 (en) * | 2004-08-18 | 2006-03-02 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| CA2603630C (en) | 2005-01-14 | 2015-06-09 | Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. | Modified exendins and uses thereof |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CN101128214A (zh) | 2005-03-18 | 2008-02-20 | 诺和诺德公司 | 长效glp-1化合物 |
| AP2007004227A0 (en) * | 2005-05-05 | 2007-12-31 | Cadila Healthcare Ltd | Novel compounds as GLP-1 agonists |
| EA012442B1 (ru) * | 2005-05-13 | 2009-10-30 | Эли Лилли Энд Компани | Пегилированные соединения glp-1 |
| EP1915393A1 (en) * | 2005-08-11 | 2008-04-30 | Eli Lilly And Company | Selective vpac2 receptor peptide agonists |
| ES2336575T3 (es) | 2005-09-22 | 2010-04-14 | Biocompatibles Uk Limited | Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa. |
| AU2006306236B2 (en) | 2005-10-26 | 2011-12-01 | Eli Lilly And Company | Selective VPAC2 receptor peptide agonists |
| ES2586236T3 (es) * | 2005-11-04 | 2016-10-13 | Glaxosmithkline Llc | Procedimientos para administrar agentes hipoglucémicos |
| EP1959986B1 (en) | 2005-11-07 | 2014-07-23 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| ES2390286T3 (es) | 2005-12-16 | 2012-11-08 | Nektar Therapeutics | Conjugados poliméricos de GLP-1 |
| BRPI0708341A2 (pt) * | 2006-02-28 | 2011-05-24 | Lilly Co Eli | agonistas peptìdicos seletivos do receptor vpac2 |
| JP2009532422A (ja) * | 2006-04-03 | 2009-09-10 | ノボ・ノルデイスク・エー／エス | Ｇｌｐ−１ペプチドアゴニスト |
| US8288339B2 (en) | 2006-04-20 | 2012-10-16 | Amgen Inc. | GLP-1 compounds |
| DE602006009631D1 (de) | 2006-05-10 | 2009-11-19 | Biocompatibles Uk Ltd | GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung |
| TWI430806B (zh) * | 2006-09-13 | 2014-03-21 | Smithkline Beecham Corp | 用於投與長效降血糖藥劑之方法 |
| MX2009008241A (es) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
| EP1972349A1 (en) * | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | GLP-1 fusion peptides conjugated to polymer(s), their production and use |
| EP1975176A1 (en) * | 2007-03-27 | 2008-10-01 | Biocompatibles UK Limited | Novel glp-1 fusion peptides, their production and use |
| JP2010535781A (ja) | 2007-08-03 | 2010-11-25 | イーライ リリー アンド カンパニー | 肥満に対する処置 |
| JP5771005B2 (ja) | 2007-10-30 | 2015-08-26 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物 |
| JP5753779B2 (ja) * | 2008-06-17 | 2015-07-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体 |
| JP6108659B2 (ja) | 2008-06-17 | 2017-04-05 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト |
| EP2344519B1 (en) | 2008-11-07 | 2016-09-28 | The General Hospital Corporation | C-terminal fragments of glucagon-like peptide-1 (glp-1) |
| PT2373681T (pt) | 2008-12-10 | 2017-04-11 | Glaxosmithkline Llc | Composições farmacêuticas de albiglutida |
| AR074811A1 (es) | 2008-12-19 | 2011-02-16 | Univ Indiana Res & Tech Corp | Profarmaco de peptido de la superfamilia de glucagon basados en amida |
| CN102459325B (zh) | 2009-06-16 | 2015-03-25 | 印第安纳大学科技研究有限公司 | 胃抑胜肽受体活化的胰高血糖素化合物 |
| KR20120123443A (ko) | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 |
| WO2011140176A1 (en) | 2010-05-04 | 2011-11-10 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| CN103179976A (zh) | 2010-05-13 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 呈现g蛋白偶联受体活性的胰高血糖素超家族肽 |
| US9127088B2 (en) | 2010-05-13 | 2015-09-08 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| KR20130102470A (ko) | 2010-06-24 | 2013-09-17 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그 |
| WO2012054861A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Glp-1 polymer conjugates having a releasable linkage |
| WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
| WO2012061466A2 (en) | 2010-11-02 | 2012-05-10 | The General Hospital Corporation | Methods for treating steatotic disease |
| EP2643009A4 (en) | 2010-11-24 | 2015-04-01 | Durect Corp | BIODEGRADABLE DRUG DELIVERY COMPOSITION |
| ES2713952T3 (es) | 2010-12-22 | 2019-05-24 | Univ Indiana Res & Tech Corp | Análogos de glucagón que muestran actividad de receptor de GIP |
| BR112013032717A2 (pt) | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
| RS56173B1 (sr) | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
| WO2013006692A2 (en) * | 2011-07-06 | 2013-01-10 | The General Hospital Corporation | Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) |
| CN102363633B (zh) * | 2011-11-16 | 2013-11-20 | 天津拓飞生物科技有限公司 | 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用 |
| CN103957927B (zh) | 2011-11-17 | 2016-11-09 | 印第安纳大学研究及科技有限公司 | 呈现糖皮质激素受体活性的胰高血糖素超家族肽 |
| EP2782590A4 (en) | 2011-11-23 | 2016-08-03 | Durect Corp | BIODEGRADABLE AND MEDIUM-RADIATED STERILIZED MEDICAMENTAL COMPOSITIONS |
| EP2864351B1 (en) | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| EP3010546B1 (en) * | 2013-06-20 | 2017-08-09 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| WO2015081891A1 (en) | 2013-12-06 | 2015-06-11 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
| EP3079668A1 (en) | 2013-12-09 | 2016-10-19 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
| WO2016083499A1 (en) | 2014-11-27 | 2016-06-02 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| EP3233898A1 (en) | 2014-12-17 | 2017-10-25 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| AU2019247936C1 (en) | 2018-04-05 | 2023-06-15 | Sun Pharmaceutical Industries Limited | Novel GLP-1 analogues |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227021B1 (en) * | 1996-08-30 | 2010-05-28 | Novo Nordisk As | Glp-1 derivatives |
| WO1999043707A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally modified glp-1 derivatives |
| DE69942306D1 (de) * | 1998-02-27 | 2010-06-10 | Novo Nordisk As | Abkömmlinge von glp-1 analogen |
| EP1100530B1 (en) | 1998-07-31 | 2003-10-08 | Novo Nordisk A/S | In-vitro stimulation of beta cell proliferation |
| JP2004528014A (ja) * | 2000-12-07 | 2004-09-16 | イーライ・リリー・アンド・カンパニー | Ｇｌｐ−１融合タンパク質 |
| EP1411968B1 (en) | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
| CA2452044A1 (en) * | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
| MXPA04003569A (es) * | 2001-10-19 | 2004-07-23 | Lilly Co Eli | Mezclas bifasicas de glp-1 e insulina. |
-
2003
- 2003-01-03 WO PCT/US2003/000001 patent/WO2003058203A2/en active Search and Examination
- 2003-01-03 CA CA002468700A patent/CA2468700A1/en not_active Abandoned
- 2003-01-03 EP EP03700026A patent/EP1585959A4/en not_active Withdrawn
- 2003-01-03 AU AU2003200839A patent/AU2003200839B2/en not_active Ceased
- 2003-01-03 AR ARP030100014A patent/AR038102A1/es unknown
- 2003-01-03 MX MXPA04006679A patent/MXPA04006679A/es unknown
- 2003-01-03 BR BRPI0306706-8A patent/BR0306706A/pt not_active IP Right Cessation
- 2003-01-03 JP JP2003558463A patent/JP4282485B2/ja not_active Expired - Fee Related
- 2003-01-03 TW TW092100093A patent/TW200306202A/zh unknown
- 2003-01-03 US US10/499,111 patent/US7482321B2/en not_active Expired - Fee Related
- 2003-01-06 PE PE2003000021A patent/PE20030820A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003200839A1 (en) | 2003-07-24 |
| BR0306706A (pt) | 2007-03-27 |
| WO2003058203A3 (en) | 2007-02-01 |
| JP2005528337A (ja) | 2005-09-22 |
| US7482321B2 (en) | 2009-01-27 |
| JP4282485B2 (ja) | 2009-06-24 |
| US20060014241A1 (en) | 2006-01-19 |
| AR038102A1 (es) | 2004-12-29 |
| TW200306202A (en) | 2003-11-16 |
| EP1585959A2 (en) | 2005-10-19 |
| CA2468700A1 (en) | 2003-07-17 |
| MXPA04006679A (es) | 2004-11-10 |
| WO2003058203A2 (en) | 2003-07-17 |
| AU2003200839B2 (en) | 2008-12-11 |
| EP1585959A4 (en) | 2007-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030820A1 (es) | Analogos extendidos de peptido 1 de tipo glucagon | |
| ES2614603T3 (es) | Procedimiento de administración de moléculas GLP-1 | |
| AR031701A1 (es) | COMPUESTOS ANA LOGOS DEL (GLP-1)-PEPTIDO-1 ANALOGO DEL GLUCAGoN, METODO PARA ESTIMULAR LOS RECEPTORES GLP-1 UTILIZANDO DICHOS COMPUESTOS Y USO DE DICHOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS PARA ESTIMULAR LA SECRECION DE INSULINA | |
| JP2019504057A5 (es) | ||
| CA2277112C (en) | Use of exendins and agonists thereof for the reduction of food intake | |
| AU2011200663B2 (en) | Exendin for treating diabetes and reducing body weight | |
| ES2283025T3 (es) | Derivados de glp-1.1. | |
| AR033998A1 (es) | Peptidos de vih, antigenos, composiciones de vacunas, kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih | |
| CA2309356A1 (en) | Novel exendin agonist compounds | |
| CA2310097A1 (en) | Novel exendin agonist compounds | |
| JP2008500281A5 (es) | ||
| JP2019504055A5 (es) | ||
| CA2373266C (en) | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus | |
| ES2291017T3 (es) | Efectos inotropicos y diureticos de la exendina y glp-1. | |
| de Heer et al. | Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1 | |
| US20130023471A1 (en) | Methods to restore glycemic control | |
| CA2550050A1 (en) | Novel glp-1 analogues linked to albumin-like agents | |
| NO325601B1 (no) | Anvendelse av et preparat for fremstilling av et medikament for a behandle organ-vevsskade. | |
| RU2009136655A (ru) | Композиция и микросфера с контролируемым высвобождением экзендина и способ получения микросферы | |
| PE20231309A1 (es) | Agonistas duales glp-1/gip | |
| AR033997A1 (es) | Peptidos regulatorios y auxiliares de vih, antigenos, composiciones de vacunas, kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih | |
| O'Harte et al. | Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice | |
| Holst | Glucagon-like peptide-1: physiology and therapeutic potential | |
| ES2550536T3 (es) | Motivos de la familia de polipéptidos pancreáticos, polipéptidos y métodos que los comprenden | |
| DK1506225T4 (da) | Hidtil ukendte peptidsammensætninger og anvendelse deraf i fremstillingen af aktive farmaceutiske sammensætninger mod hepatitis c-virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |